Aptevo Therapeutics Inc
APVO
View Detailed Chart
9.445USD
+0.415+4.60%
Close 01/16, 16:00（ET）Quotes delayed by 15 min
7.25MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+4.60%
5 Days
+5.30%
1 Month
+782.71%
6 Months
+211.72%
Year to Date
+0.16%
1 Year
-89.41%
View Detailed Chart
TradingKey Stock Score of Aptevo Therapeutics Inc
Currency: USD Updated: 2026-01-16Key Insights
Aptevo Therapeutics Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 192 out of 396 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 7560.00.In the medium term, the stock price is expected to trend up.Despite a strong stock market performance and outperforming fundamentals over the past month, the technicals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Aptevo Therapeutics Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Negative
Aptevo Therapeutics Inc Highlights
StrengthsRisks
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
Fairly Valued
The company’s latest PE is 0.00, at a medium 3-year percentile range.
Institutional Buying
The latest institutional holdings are 27.57K shares, increasing 47.86% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 0.00 shares of this stock.
Analyst Rating
Based on
1
analysts
Buy
Current Rating
7560.000
Target Price
+79942.35%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Aptevo Therapeutics Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Aptevo Therapeutics Inc Info
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel bispecific immunotherapies for the treatment of cancer. The Company has two clinical candidates: Mipletamig and ALG.APV-527. Mipletamig is being evaluated in RAINIER, a two-part Phase 1b/2 trial for the treatment of frontline acute myeloid leukemia in combination with standard-of-care venetoclax + azacitidine. Mipletamig has received orphan drug designation for AML according to the Orphan Drug Act. ALG.APV-527, a bispecific conditional 4-1BB agonist, only active upon simultaneous binding to 4-1BB and 5T4, is being co-developed with Alligator Bioscience and is being evaluated in a Phase 1 clinical trial for the treatment of multiple solid tumor types likely to express 5T4. The Company has three pre-clinical candidates with different mechanisms of action designed to target a range of solid tumors. All pipeline candidates are created from two proprietary platforms, ADAPTIR and ADAPTIR-FLEX.
Ticker SymbolAPVO
CompanyAptevo Therapeutics Inc
CEOWhite (Marvin L)
Websitehttps://aptevotherapeutics.com/
FAQs
What is the current price of Aptevo Therapeutics Inc (APVO)?
The current price of Aptevo Therapeutics Inc (APVO) is 9.445.
What is the symbol of Aptevo Therapeutics Inc?
The ticker symbol of Aptevo Therapeutics Inc is APVO.
What is the 52-week high of Aptevo Therapeutics Inc?
The 52-week high of Aptevo Therapeutics Inc is 1807.200.
What is the 52-week low of Aptevo Therapeutics Inc?
The 52-week low of Aptevo Therapeutics Inc is 7.660.
What is the market capitalization of Aptevo Therapeutics Inc?
The market capitalization of Aptevo Therapeutics Inc is 7.25M.
What is the net income of Aptevo Therapeutics Inc?
The net income of Aptevo Therapeutics Inc is -24.13M.
Is Aptevo Therapeutics Inc (APVO) currently rated as Buy, Hold, or Sell?
According to analysts, Aptevo Therapeutics Inc (APVO) has an overall rating of Buy, with a price target of 7560.000.
What is the Earnings Per Share (EPS TTM) of Aptevo Therapeutics Inc (APVO)?
The Earnings Per Share (EPS TTM) of Aptevo Therapeutics Inc (APVO) is -1097397.607.
Related Instruments
+0.53%
-0.41%
-1.11%
+0.43%
+0.83%
-1.93%
+9.12%
+0.12%
+3.01%
-0.93%
-1.85%
-2.40%
+0.56%
-0.43%
-1.83%
+0.61%
-1.20%
0.00%
-0.50%
-1.04%Popular Symbols
255.530
-2.680 (-1.04%)
186.230
-0.820 (-0.44%)
92474.590
-637.360 (-0.69%)
221.510
-0.590 (-0.27%)
3181.210
-30.600 (-0.95%)
437.500
-1.070 (-0.24%)
4664.140
-6.410 (-0.14%)
59.374
+0.014 (+0.02%)
1.164
-0.001 (-0.07%)
158.164
+0.039 (+0.03%)
